Post hoc single-centre analysis of 43 HELIOS-B participants with ATTR cardiomyopathy: vutrisiran vs placebo was associated with higher LVEF (+19.18%), lower LV mass (−23.58 g) and lower ECV (−6.56%) on cardiac MRI; few had 3-year scans (17).
Secondary analysisn = 43
Razvi et al. Vutrisiran Treatment and Changes in Cardiac Parameters and Amyloid Burden Assessed by Cardiovascular MRI